Ethosuximide Pediatric Dose — Anticonvulsant
Ethosuximide is a succinimide anticonvulsant that reduces low-threshold T-type calcium currents in thalamic neurons, suppressing the spike-and-wave discharges characteristic of absence seizures. It is considered a first-line agent for childhood absence epilepsy (petit mal) and is administered orally as a syrup or capsule formulation.
Pediatric Dosing
| Age Group | Initial Dose | Frequency | Max Per Dose |
|---|---|---|---|
| <6 years | 15 mg/kg/day PO, divided | Every 12 hours | 250 mg/dose |
| ≥6 years | 250 mg PO | Every 12 hours | — |
For children under 6, dosing is weight-based. Worked example: For a 15 kg child: 15 kg × 15 mg/kg/day = 225 mg/day, divided into two doses of approximately 112.5 mg every 12 hours (not to exceed 250 mg per dose). For children 6 years and older, a fixed initial dose of 250 mg every 12 hours is used regardless of weight.
Dose titration beyond the initial dose should be guided by clinical response and tolerability; consult institutional protocol for maintenance and target dose ranges.
Indications and Clinical Context
Ethosuximide is indicated for the management of absence (petit mal) seizures in pediatric patients. It is recognized as a first-line pharmacotherapy for childhood absence epilepsy in standard pediatric neurology guidelines, offering efficacy comparable to valproic acid with a more favorable cognitive side-effect profile. It is not effective against generalized tonic-clonic or focal seizures and should not be used as monotherapy when these seizure types coexist.
The weight-based dosing strategy for children under 6 years reflects the higher per-kilogram clearance seen in younger patients, while older children typically tolerate a standard fixed starting dose. Therapy is generally initiated at the lowest effective dose and titrated as needed based on seizure control and tolerability.
Administration and Monitoring
Ethosuximide is administered orally as either a syrup (250 mg/5 mL) or capsule formulation. Doses are given in divided doses every 12 hours to maintain steady plasma concentrations. It should be taken with food to minimize gastrointestinal adverse effects, which are among the most common complaints (nausea, vomiting, anorexia, abdominal discomfort).
- Route: Oral only; no parenteral formulation is available.
- Common adverse effects: GI upset, drowsiness, hiccups, headache, and behavioral changes.
- Serious adverse effects: Rare systemic lupus erythematosus-like syndrome, blood dyscrasias (leukopenia, aplastic anemia) — periodic CBC monitoring is advisable.
- Contraindications: Known hypersensitivity to succinimide derivatives.
- Monitoring: Serum ethosuximide levels, CBC, liver function tests, and clinical seizure assessment per institutional protocol.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.